[Federal Register: November 2, 2007 (Volume 72, Number 212)]
[Notices]
[Page 62224]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr02no07-38]
[[Page 62224]]
-----------------------------------------------------------------------
DEPARTMENT OF DEFENSE
Office of the Secretary
Meeting of the Uniform Formulary Beneficiary Advisory Panel
AGENCY: Assistant Secretary of Defense (Health Affairs), Department of
Defense.
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: Under the provisions of the Federal Advisory Committee Act of
1972 (5 U.S.C., Appendix, as amended) and the Sunshine in the
Government Act of 1976 (U.S.C. 522b, as amended) the Department of
Defense announces the following Federal Advisory Committee Meeting.
Name of Committee: Uniform Formulary Beneficiary Advisory Panel
(hereafter referred to as the Panel).
Date of Meeting: Thursday, January 10, 2008.
Location: Naval Heritage Center Theater, 701 Pennsylvania Avenue
NW., Washington, DC 20004.
Time: 8 a.m. to 4 p.m.
Purpose of Meeting: The Panel will review and comment on
recommendations made to the Director, TRICARE Management Activity, by
the Pharmacy and Therapeutics (P&T) Committee regarding the Uniform
Formulary.
Meeting Agenda: Sign-In; Welcome and Opening Remarks; Opportunity
for Public Citizen Comments; Scheduled Therapeutic Class Reviews--
Targeted Immunomodulatory Biologics (TIBs), BPH Alpha Blockers (BPH-
ABs), Adrenergic Blocking Agents (ABAs) and Designated Newly Approved
Drugs; Panel Discussions and Vote, and comments following each
therapeutic class review.
Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and
41 CFR 102-3.140 through 102-3.165, and the availability of space this
meeting is open to the public. Seating is limited and will be provided
only to the first 220 people signing in. All persons must sign in
legibly.
Written Statements: Pursuant to 41 CFR 102-3.105(j) and 102.3.140,
the public or interested organizations may submit written statements to
the membership of the Panel at any time or in response to the stated
agenda of a planned meeting. Written statements should be submitted to
the Panel's Designated Federal Officer. The Designated Federal
Officer's contact information can be obtained from the GSA's FACA
Database--http://www.fido.gov/facadatabase/public.asp.
Written statements that do not pertain to the scheduled meeting of
the Panel may be submitted at any time. However, if individual comments
pertain to a specific topic being discused at a planned meeting then
these statements must be submitted no later than five (5) business days
prior to the meeting in question. The Designated Federal Officer will
review all submitted written statements and provide copies to all the
committee members.
Public Comments: In addition to written statements, the Panel will
set will set aside one (1) hour for individual or interested groups to
address the Panel. To ensure consideration of their comments,
individuals and interested groups should submit written statements as
outlined in this notice. Additionally, they will be afforded the
opportunity to address the Panel. Registration for addressing the Panel
in on a first-come, first-serve basis. Those wishing to address the
Panel will be given no more than five (5) minutes to present their
comments, and at the end of the one (1) hour time period no further
public comments will be accepted.
FOR FURTHER INFORMATION CONTACT: Major Travis Watson, Designated
Federal Officer, Uniform Formulary Beneficiary Advisory Panel, Skyline
5, Suite 810-5111 Leesburg Pike, Falls Church, Virginia 22041-3206,
Telephone: (703) 681-2890--Fax: (703) 681-1940, E-mail Address:
baprequests@tma.osd.mil.
Dated: October 26, 2007.
L.M. Bynum,
Alternate OSD Federal Register Liaison Officer.
[FR Doc. 07-5456 Filed 11-1-07; 8:45 am]
BILLING CODE 5001-06-M